Our Current Trials

Condition	Trial Name	Sponsor
Solid Tumors	1403-0002: MDM2 Inhibitor BI 907828 and Anti PD-1 Antibody Ezabenlimab in Select Solid Tumors	Boehringer Ingelheim
Solid Tumors	1719-001: MRTX1719 in MTAP Deleted Advanced Solid Tumors	Mirati Therapeutics, Inc.
Rectal Cancer	19-288: Neoadjuvant TSR-042 (dostarlimab) for Patients with Rectal Adenocarcinoma	Memorial Sloan Kettering Cancer Center
Breast Cancer	ASCENT-03: Sacituzumab Govitecan as First Line Treatment for Patients With Triple Negative Breast Cancer	Gilead Sciences
Breast Cancer	ASCENT-04: Sacituzumab Govitecan in Combination With Pembrolizumab as First Line Treatment for Patients With PD-L1 Expressing Triple Negative Breast Cancer	Gilead Sciences
Breast Cancer	ASCENT-05: Adjuvant Sacituzumab Govitecan Plus Pembrolizumab for Patients with Triple Negative Breast Cancer	Gilead Sciences, Inc.
Cachexia in Colorectal or Pancreatic Cancer	AV-380-22-102: Study of GDF-15 Inhibitor AV-380 for the Treatment of Cachexia in Patients with Metastatic Colorectal or Pancreatic Cancer Receiving First Line Chemotherapy	AVEO Pharmaceuticals, Inc.
Solid Tumors	BI 1403-0001: MDM2 inhibitor BI 907828 in MDM2 Amplified Advanced Solid Tumors	Boehringer Ingelheim
Breast Cancer	BRI-ROL-001: SV-BR-1-GM Regimen in Combination With Retifanlimab in Patients With Metastatic or Locally Recurrent Breast Cancer Who Have Failed Standard Therapy	BriaCell Therapeutics Corporation
Biliary Tract Cancer, Pancreatic Cancer	Brightline-2: MDM2 Inhibitor BI 907828 in MDM2 amplified, TP53 Wild Type Pancreatic or Biliary Tract Cancer	Boehringer Ingelheim
Solid Tumor or Lymphoma	CS5001-101: A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas	CStone Pharmaceuticals
Solid Tumors	DAY101-102: Pan-RAF Inhibitor DAY101 for Patients with Relapsed/Refractory MAPK-Altered Solid Tumors	Day One Biopharmaceuticals, Inc.
Breast Cancer	DESTINY-Breast09: Trastuzumab deruxtecan for First Line Treatment of Advanced/Metastatic HER2-Positive Breast Cancer	AstraZeneca
Breast Cancer	ELEVATE: Elacestrant Combinations for the Treatment of ER+ HER2- Metastatic Breast Cancer After CDK4/6 Inhibitor	Stemline Therapeutics, Inc.
Central Nervous System Cancer	F8294-201b: BRAF Inhibitor FORE8394 in Recurrent/Refractory BRAF V600E Mutant CNS Malignancy	Fore Biotherapeutics
Solid Tumors	F8394-201a: BRAF Inhibitor FORE8394 for the Treatment of BRAF Fusion Positive Advanced Solid Tumors	Fore Biotherapeutics
Gastric or Gastroesophageal Junction Cancer	GEMINI-C: First Line Treatment for Patients with an Advanced/Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma	AstraZeneca
Head and Neck Squamous Cell Carcinoma	GS-US-548-5916: Magrolimab Combinations in Recurrent or Metastatic HNSCC	Gilead Sciences, Inc.
Non-Small Cell Lung Cancer	HARMONIC: A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung Adenocarcinoma	Lantern Pharma Inc.
Colon or Rectal Cancer	KRYSTAL-10: Adagrasib in KRAS G12C Mutated Colorectal Cancer	Mirati Therapeutics, Inc.
Non-Small Cell Lung Cancer	KRYSTAL-17: Adagrasib Combinations in Patients with KRAS G12C Mutation	Mirati Therapeutics, Inc.
Solid Tumors	KRYSTAL-1: Multiple Cohort Study of Adagrasib Monotherapy or Combinations for Patients With KRAS G12C Mutant Solid Tumors	Mirati Therapeutics Inc.
Colon or Rectal Cancer	LUT014 Gel for EGFR-Inhibitor Induced Acneiform Rash	Lutris Pharma Ltd.
Non-Hodgkin Lymphoma	MorningSun: Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies	Genentech, Inc.
Hyperkalemia/Chronic Kidney Disease	NYH-01: Hyperkalemia/Chronic Kidney Disease	Relypsa
Solid Tumors	PRECISION 1: Nab-Sirolimus for the Treatment of Patients With TSC1/2 Mutant Advanced or Metastatic Solid Tumor	Aadi Bioscience, Inc.
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma	PRT1419-03: PRT1419 in Patients with Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, or Select B-Cell Malignancies	Prelude Therapeutics
ITP, wAIHA, CAD	RUBY-4: Povetacicept (ALPN-303) for Patients with Autoimmune Cytopenias	Alpine Immune Sciences, Inc.
Breast Cancer	SERENA-6: AZD9833+ CDK4/6 Inhibitor in HR+/HER2-MBC With Detectable ESR1m Before Progression	AstraZeneca
Breast Cancer	SPI-GCF-104: Same Day Administration of Eflapegrastim to Treat Neutropenia in Patients Being Treated With Neo/Adjuvant Docetaxel Plus Cyclophosphamide	Spectrum Pharmaceuticals, Inc.
Multiple Myeloma	TAK-573-2001: Modakafusp alfa in Combination with Daratumumab for the Treatment of Relapsed/Refractory Multiple Myeloma	Takeda Development Center Americas, Inc
Solid Tumors	TAPISTRY: Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You Platform Study	Hoffmann-La Roche
Non-Small Cell Lung Cancer	TROPION-Lung07: Datopotamab Deruxtecan Combinations vs Standard Chemo/Immunotherapy for the First Line Treatment of Non-Squamous Non-Small Cell Lung Cancer	Daiichi Sankyo, Inc.
Ovarian, Fallopian Tube or Primary Peritoneal Cancer	ZN-c3-005: Phase 2 Study of ZN‑c3 in High-Grade Serous Ovarian Cancer	K-Group, Beta, Inc.
Cancer Diagnosis	[Registry] MSK-IMPACT/ACCESS Genomic Profiling in Cancer Patients	Memorial Sloan Kettering Cancer Center
Various Indications	[Sample Collection] Clinical Biospecimen Procurement Protocol to Support Advancements in Medical Diagnoses of Diseases (PROMEDx)	Precision for Medicine
Solid Tumors	[Sample Collection] Collection and Distribution of Biofluids for Research Purposes	Bluestar Genomics
Solid Tumors	[Sample Collection] Detecting cancers Earlier Through Elective plasma-based Cancer SEEK Testing (DETECT-ASCEND 2)	Exact Sciences Thrive LLC
Various Indications	[Sample Collection] Discovery and Evaluation of Biomarkers/Pharmacogenomics for the Diagnosis and Personalized Management of Patients (MTG-022)	MT Group
Various Indications	[Sample Collection] Prospective Collection of Samples for Research (SERATRIALS-05035)	SERATRIALS, LLC.
Solid Tumors	[Sample Collection] Vallania: A Case Control Study for the Development of Multiomics Blood Tests for Cancer Screening	Freenome Holdings Inc.
Solid Tumors	eNRGy: HER2xHER3 Bispecific Antibody MCLA-128 for the Treatment of an Advanced or Metastatic Solid Tumor Malignancy With a Documented NRG1 Fusion	Merus N.V.

Our Current Trials

Call Us

COVID-19 - Information